$AVGR,,I am in this at $.45 per share and although the charts look like it should go up from where it is, I came across several articles on lawsuits which have been filed. Sometimes these ar filed by firms to get a settlement so they go away, sometimes not. Here is one:
Robbins Arroyo LLP: Avinger, Inc. (AVGR) Misled Shareholders According to a Recently Filed Class Action
June 09, 2017 05:21 PM Eastern Daylight Time
SAN DIEGO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Avinger, Inc. (NasdaqGM: AVGR) on behalf of all purchasers of Avinger securities pursuant to the company's initial public offering on January 30, 2015 (the "Offering"
, for alleged violations of the Securities Act of 1933 by Avinger's officers and directors. Avinger, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe.
View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/avinger-inc
Avinger Accused of Filing Misleading Registration Statement
According to the complaint, on January 30, 2015, Avinger held the Offering, selling five million shares at $13.00 per share, raising approximately $56,897,000 in net proceeds. The complaint alleges that Avinger's registration statement issued in connection with the Offering failed to disclose that the company's Pantheris and Lumivascular products had substantial reliability issues that would negatively affect sales of the company's products. On July 12, 2016, Avinger announced disappointing preliminary second quarter 2016 results, attributing its results to lower than expected utilization of Pantheris. As a result, Avinger lowered its full year revenue guidance from a range of $25 to $30 million to a range of $19 to $23 million, causing its stock to drop approximately 40%. Then, on April 10, 2017, Avinger announced that it encountered challenges with product reliability and the commercialization of its Lumivascular technology, and that it was reducing its workforce by approximately 33%. On this news, Avinger's stock fell $1.00 per share, or 62.5%, to close at $0.60 per share on April 11, 2017.
Avinger Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
Robbins Arroyo LLP: Avinger, Inc. (AVGR) Misled Shareholders According to a Recently Filed Class Action
June 09, 2017 05:21 PM Eastern Daylight Time
SAN DIEGO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Avinger, Inc. (NasdaqGM: AVGR) on behalf of all purchasers of Avinger securities pursuant to the company's initial public offering on January 30, 2015 (the "Offering"
, for alleged violations of the Securities Act of 1933 by Avinger's officers and directors. Avinger, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/avinger-inc
Avinger Accused of Filing Misleading Registration Statement
According to the complaint, on January 30, 2015, Avinger held the Offering, selling five million shares at $13.00 per share, raising approximately $56,897,000 in net proceeds. The complaint alleges that Avinger's registration statement issued in connection with the Offering failed to disclose that the company's Pantheris and Lumivascular products had substantial reliability issues that would negatively affect sales of the company's products. On July 12, 2016, Avinger announced disappointing preliminary second quarter 2016 results, attributing its results to lower than expected utilization of Pantheris. As a result, Avinger lowered its full year revenue guidance from a range of $25 to $30 million to a range of $19 to $23 million, causing its stock to drop approximately 40%. Then, on April 10, 2017, Avinger announced that it encountered challenges with product reliability and the commercialization of its Lumivascular technology, and that it was reducing its workforce by approximately 33%. On this news, Avinger's stock fell $1.00 per share, or 62.5%, to close at $0.60 per share on April 11, 2017.
Avinger Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
1
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
